Trials / Conditions / Transfusion-dependent Anemia

Transfusion-dependent Anemia

13 registered clinical trials studyying Transfusion-dependent Anemia — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD NCT06525948	Peking Union Medical College Hospital	Phase 4
Recruiting	Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery NCT06414031	Ulrich Ronellenfitsch, MD	Phase 3
Recruiting	Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/In NCT05924100	Associazione Qol-one	Phase 2
Completed	Prediction of Transfusion-Associated Complications NCT05466370	Kepler University Hospital	—
Unknown	The Safety and Efficiency of Luspatercept in Chinese Adults With Transfusion Dependent β-thalassemia: a Real-w NCT05462548	Sun Yat-sen University	Phase 4
Unknown	Prospective Study on Feto-maternal outcoMe In aNemIc womEn NCT05739097	Casa Sollievo della Sofferenza IRCCS	—
Completed	Machine Learning-Based Prediction of Major Perioperative Allogeneic Blood Requirements in Cardiac Surgery NCT04856618	Kepler University Hospital	—
Terminated	Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplasti NCT03643042	Lille Catholic University	N/A
Completed	An Analysis of Blood Management in Patients Having Hip or Knee Arthroplasty NCT04303910	Siriraj Hospital	—
Completed	Knowledge and Attitude in Perioperative Erythrocyte Transfusion in Medical Personnel in Siriraj Hospital NCT04155021	Siriraj Hospital	—
Completed	Complications Associated With Intraoperative Hypothermia. NCT05203016	Instituto de Investigación Hospital Universitario La Paz	—
Active Not Recruiting	Liberal Transfusion Strategy in Elderly Patients NCT03369210	Johann Wolfgang Goethe University Hospital	Phase 3
Completed	Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) NCT02435212	Novartis Pharmaceuticals	Phase 2